By Camille Mojica Rey, Contributing Writer
This is the third article in a five-part Life Science Leader series examining the current state of the counterfeit medicines problem.
It’s a sobering trend for the pharmaceutical industry. The counterfeit medicines market is growing at twice the rate of the market for legitimate prescription drugs. That’s according to the Center for Medicine in the Public Interest, a New York-based research group partially funded by the pharmaceutical industry. The organization estimates that the sale of fake pharmaceuticals generated $75 billion in 2010. The group estimates that the figure for 2016 will rise to $95 billion.